Pozen news from FierceBiotech

> Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...

AstraZeneca and Pozen are starting Phase III trial of PN400, an experimental drug for arthritis pain that combines AstraZeneca's heartburn drug Nexium with the anti-inflammatory drug naproxen. In Read more...

Pozen stock took a painful dive this morning after GlaxoSmithKline announced that their two-in-one migraine drug Trexima would be delayed yet again--this time to satisfy Read more...

> An August 1 FDA action date for Pozen's migraine drug Trexima is looming, and the analysts are paying close attention as the decision deadline nears. Report

> Manhattan Pharmaceuticals says it will …

Read more...

New York Times scribe Andrew Pollack takes a careful look at the current trend of making new drugs out of combinations of old therapies. Despite reporting one trial failure last week, CombinatoRx is out in the lead on this one. Researchers at the company are systematically running through the possible combinations of 2,000 generic drugs. But …

Read more...

Shares of Pozen sank about 10 percent this morning after it announced that the FDA had asked for more data on the migraine drug Trexima--a combination of sumatriptan and naproxen sodium--before it can be approved. The Trexima application had already been found wanting last June. This new warning came after the agency found the company's response insufficient. Pozen says it will submit more information by the end of the year, but adds that it feels the data already demonstrates the drug's …

Read more...

> Nucryst Pharmaceuticals announced that a mid-stage trial of its topical cream for dermatitis did not achieve its goal, according to a preliminary review of the data. The company plans to continue to study other uses of the drug. Report

> Chutes & Ladders: BioCryst Pharmaceuticals announced that Charles E. Bugg, Ph.D., the company's chairman, CEO and co-founder, has informed …

Read more...

Read more...

Shares of Pozen shot up 30 percent this morning when the company announced that it has signed a rich deal to develop a pain medication with AstraZeneca that will combine therapies from each company. Pozen gets $40 million up front, $160 million in potential milestone payments and $175 million for hitting sales targets along with royalties. The deal will pair the nonsteroidal anti-inflammatory drug naproxen with esomeprazole magnesium, the active ingredient in Nexium. The combinational …

Read more...

> Canada's Occulogix says it will file an application for an Investigational Device Exemption with the FDA for its RHEO system to treat dry age-related macular degeneration. Occulogix says it met with representatives of the FDA last week and that they asked for a new study of the RHEO System. Report

> Holly Springs, NC …

Read more...